Opioids and other medications may result in adverse event or death

8 February 2017
thomas-frederickson-large

With opioid abuse in the USA now a major crisis and the use of certain non-opioids in combination with these drugs a major potential risk, Thomas W Frederickson, lead author of the Society of Hospital Medicine guide Reducing Adverse Drug Events Related to Opioids (RADEO), writes about reducing the risk of death and the related US Food and Drug Administration (FDA) warnings in an Expert View piece.

It is described by some as ‘dead in bed’ syndrome. Respiratory arrest and death related to opioids has an incidence that is hard to measure, but the patient stories of near-misses sudden deaths following routine surgeries are real.

In a hospital setting, improper use of opioids can lead to dangerous sedation, respiratory depression, and death. The risks are compounded because opioids are the most prescribed class of medication in hospitals, leading it to be the second most common class of medication to cause adverse patient events. The good news is that, with the implementation of a rigorous quality improvement plan, patient harm from opioid-related respiratory depression can be preventable.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical